P17.22.B SILMET TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE STAT3 INHIBITOR SILIBININ IN PREVENTING INTRACRANIAL RECURRENCE AFTER COMPLETE RESECTION OF A SINGLE BRAIN METASTASIS FROM NON-SMALL-CELL LUNG CANCER (NSCLC) OR BREAST CANCER
P17.22.B SILMET试验：一项随机、安慰剂对照研究，旨在评估STAT3抑制剂西利宾在预防非小细胞肺癌（NSCLC）或乳腺癌单发脑转移瘤完全切除术后颅内复发方面的疗效。
期刊:
影响因子:
doi:10.1093/heapol/czx063
Witter, Sophie; Govender, Veloshnee; Ravindran, T K Sundari; Yates, Robert; Mone, Fabia Hannan; Keith, Regina Murphy; Sarker, Atiqur Rahman; Noonan-Gunning, Sharon; Tewfik, Ihab; Edwards, Dorothy F; McAlister, Jennifer; Nuttkinson, Bonnie L; Walaszek, Art; Chin, Nathaniel A; Pellerino, A; Pace, A; Angileri, F; Caffo, M; Gatti, M; Benicelli, E; Bertero, L; Ricci, A; Mangherini, L; Garbossa, D; Priego, N; Bosch-Barrera, J; Valiente, M; Rudà, R; Soffietti, R
肺癌
肿瘤
肿瘤免疫
JAK/STAT
神经科学
乳腺癌
STAT3
CLC
细胞生物学
MET
